| | | | The secondary Biotech index [XBI] has been in a 5 year consolidation after topping in 2021, and almost all small Biotechs have been at their lows for months and years since. Shorting the index when it rises has become standard operating procedure for some. Nice smaller companies, some with approved products, have been on their knees lately, because few acquisitions have been made and they have a difficult time raising capital. IBRX falls into that category as short interest continues to climb, and it's no shock that investors are frustrated at this time. All that being said, we continue to be very bullish about Anktiva and its long term trajectory, because we have seen nothing discouraging so far. In fact the progress is faster than we projected with Dr. PSS and Adcock trying to push the envelope. Just the success with rBCG is impressive to us. We don't know where Tinfoil Hat has been, but in late February he was over the moon about rBCG and it's potential. We would be shocked if he wasn't still fully invested, but he is young and has plenty on his plate. We understand the impatience with IBRX, but are comforted believing that PSS could sell the company, and his approved Antica for several times its current price with a single phone call to a number of BP's. It may be a while before small BIOS bottom out, but when they do the whole group will double and triple from these oversold prices very quickly. We just need a catalyst. All this is our current thinking based on what we know now, but big potential surprises are on the near horizon for IBRX. |
|
